NCT06820086View on ClinicalTrials.gov

Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

2,500

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

February 28, 2030

Study Completion Date

February 28, 2033

Conditions
PRS-based Primary Prevention of CVD
Interventions
DRUG

Rosuvastatin 20mg

Preventive statin treatment with rosuvastatin 20mg, 1 tablet per day, for healthy individuals with top 20% CAD PRS.

Trial Locations (2)

Unknown

North Estonia Medical Centre, Tallinn

Tartu University Hospital, Tartu

All Listed Sponsors
collaborator

Funding: European Union (the sponsor does not fund the study)

UNKNOWN

collaborator

The Estonian Health Insurance Fund

UNKNOWN

collaborator

North Estonian Medical Center

UNKNOWN

collaborator

Tartu University Hospital

OTHER

lead

Mikk JÜRISSON

OTHER